☰

Changmeng Cai, Ph.D. - Publications

Affiliations: 
2007 The University of Toledo 
Area:
Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

70 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Besschetnova A, Han W, Liu M, Gao Y, Li M, Wang Z, Labaf M, Patalano S, Venkataramani K, Muriph RE, Macoska JA, Siegfried KR, Evans J, Balk SP, Gao S, ... ... Cai C, et al. Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression. Cancer Research Communications. 3: 1716-1730. PMID 37663929 DOI: 10.1158/2767-9764.CRC-23-0208  0.61
2023 Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, Besschetnova A, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Vedadi M, Arrowsmith CH, ... ... Cai C, et al. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proceedings of the National Academy of Sciences of the United States of America. 120: e2220472120. PMID 37549269 DOI: 10.1073/pnas.2220472120  0.503
2023 Li M, Liu M, Han W, Wang Z, Han D, Patalano S, Macoska JA, Balk SP, He HH, Corey E, Gao S, Cai C. LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer. Cancer Research. PMID 36877164 DOI: 10.1158/0008-5472.CAN-22-2433  0.465
2022 Labaf M, Li M, Ting L, Karno B, Zhang S, Gao S, Patalano S, Macoska JA, Zarringhalam K, Han D, Cai C. Increased expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2. Frontiers in Oncology. 12: 1021845. PMID 36408179 DOI: 10.3389/fonc.2022.1021845  0.618
2022 Han W, Liu M, Han D, Toure AA, Li M, Besschetnova A, Wang Z, Patalano S, Macoska JA, Lam HM, Corey E, He HH, Gao S, Balk SP, Cai C. Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 35121110 DOI: 10.1016/j.ymthe.2022.01.039  0.544
2022 Liao Y, Chen CH, Xiao T, de la Peña Avalos B, Dray EV, Cai C, Gao S, Shah N, Zhang Z, Feit A, Xue P, Liu Z, Yang M, Lee JH, Xu H, et al. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proceedings of the National Academy of Sciences of the United States of America. 119. PMID 35031563 DOI: 10.1073/pnas.2105898119  0.433
2022 Han W, Liu M, Han D, Li M, Toure AA, Wang Z, Besschetnova A, Patalano S, Macoska JA, Gao S, He HH, Cai C. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Oncogene. 41: 852-864. PMID 34975152 DOI: 10.1038/s41388-021-02135-3  0.562
2021 Han D, Owiredu JN, Healy BM, Li M, Labaf M, Steinfeld JS, Patalano S, Gao S, Liu M, Macoska JA, Zarringhalam K, Siegfried KR, Yuan X, Rebbeck TR, Cai C. Susceptibility-associated genetic variation in NEDD9 contributes to prostate cancer initiation and progression. Cancer Research. PMID 33632899 DOI: 10.1158/0008-5472.CAN-20-3042  0.47
2020 Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein & Cell. PMID 32946061 DOI: 10.1007/S13238-020-00786-8  0.621
2020 Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D, Luong MP, Owiredu J, Liang Y, Ahmed M, Petricca J, ... ... Cai C, et al. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nature Genetics. PMID 32868907 DOI: 10.1038/S41588-020-0681-7  0.621
2020 Cai C. A Novel Mechanism to Induce BRCAness in Cancer Cells. Cancer Research. 80: 2977-2978. PMID 32669350 DOI: 10.1158/0008-5472.Can-20-1451  0.415
2019 Cai C, Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH. ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer. Cancer Research. PMID 31444154 DOI: 10.1158/0008-5472.Can-19-0815  0.672
2019 Wang Z, Gao S, Han D, Han W, Li M, Cai C. LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells. Frontiers in Oncology. 9: 721. PMID 31428587 DOI: 10.3389/Fonc.2019.00721  0.657
2019 Gao S, Chen S, Han D, Barrett D, Han W, Ahmed M, Patalano S, Macoska JA, He HH, Cai C. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Research. PMID 31324883 DOI: 10.1038/S41422-019-0203-2  0.539
2019 Zhou F, Gao S, Han D, Han W, Chen S, Patalano S, Macoska JA, He HH, Cai C. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene. PMID 30718921 DOI: 10.1038/S41388-019-0730-9  0.635
2019 Han D, Chen S, Han W, Gao S, Owiredu J, Patalano SC, Macoska JA, He HH, Cai C. Abstract 3482: ZBTB7A mediates the transcriptional repression activity of androgen receptor in prostate cancer cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3482  0.715
2019 Gao S, Chen S, Han D, Han W, Owiredu JN, Balk SP, He HH, Cai C. Abstract 923: FOXA1 chromatin binding is regulated by LSD1-mediated methylation in prostate cancer cells Cancer Research. 79: 923-923. DOI: 10.1158/1538-7445.Am2019-923  0.644
2019 Li M, Han D, wang z, gao s, Cai C. Abstract LB-A14: Combinational therapy by targeting LSD1 and BRD4 in prostate cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Lb-A14  0.653
2019 wang z, Gao S, cai C. Abstract LB-A13: LSD1 activates both PI3K/AKT and AR signaling in prostate cancer cells Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Lb-A13  0.604
2018 Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. Cancer Research. PMID 30012673 DOI: 10.1158/0008-5472.Can-17-3615  0.604
2018 Han W, Han D, Chen S, Gao S, He H, Cai C. Abstract A066: Rb and ZBTB7A cooperatively mediate the transcriptional repression function of androgen receptor Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A066  0.642
2017 Han W, Gao S, Barrett D, Ahmed M, Han D, Macoska JA, He HH, Cai C. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene. PMID 29059155 DOI: 10.1038/Onc.2017.385  0.684
2017 Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, ... ... Cai C, et al. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Research. PMID 28916652 DOI: 10.1158/0008-5472.Can-17-0496  0.691
2017 Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Molecular Cancer Research : McR. 15: 521-531. PMID 28465296 DOI: 10.1158/1541-7786.Mcr-16-0315-T  0.6
2017 Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Exploiting AR Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Molecular Cancer Research : McR. PMID 28119432 DOI: 10.1158/1541-7786.MCR-16-0315-T  0.526
2017 Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SP. Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Research. PMID 28062857 DOI: 10.1093/Nar/Gkw1291  0.696
2017 Nyquist MD, Corella AN, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Nelson P, Mostaghel EA. Preclinical discovery and validation of high-dose androgen drug synergies for the treatment of prostate cancer. Journal of Clinical Oncology. 35: 202-202. DOI: 10.1200/Jco.2017.35.6_Suppl.202  0.55
2017 Gao S, Chen S, Han D, Han W, Balk SP, He HH, Cai C. Abstract 5497: LSD1 modulates androgen receptor cistrome in prostate cancer via regulation of FOXA1 chromatin binding Cancer Research. 77: 5497-5497. DOI: 10.1158/1538-7445.Am2017-5497  0.687
2017 Han D, Owiredu J, Valencia K, Cai C. Abstract 4476: A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer Cancer Research. 77: 4476-4476. DOI: 10.1158/1538-7445.Am2017-4476  0.587
2016 Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget. PMID 28036278 DOI: 10.18632/Oncotarget.14296  0.643
2016 Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C. Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Reports. 17: 966-976. PMID 27760327 DOI: 10.1016/J.Celrep.2016.09.064  0.782
2016 Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X. SOX9 drives WNT pathway activation in prostate cancer. The Journal of Clinical Investigation. PMID 27043282 DOI: 10.1172/Jci78815  0.641
2016 Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel E, Nelson PS, Taplin ME, Balk SP, ... Cai C, et al. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26936914 DOI: 10.1158/1078-0432.Ccr-15-2309  0.649
2016 Liu X, Gao Y, Cai C, Balk S, Chen S. Abstract A13: Androgen receptor functions as an adaptor protein for recruitment of protein phosphatase 1a to chromatin and CDK9 mobilization Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-A13  0.695
2016 Gao S, Han D, Gao Y, He H, Han W, Balk S, Cai C. Abstract 1976: Androgen receptor activity is reprogrammed by lysine-specific demethylase 1 in prostate cancer Cancer Research. 76: 1976-1976. DOI: 10.1158/1538-7445.Am2016-1976  0.666
2015 Liu X, Han W, Gulla S, Simon NI, Gao Y, Cai C, Yang H, Zhang X, Liu J, Balk SP, Chen S. Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget. PMID 26636645 DOI: 10.18632/Oncotarget.6434  0.78
2015 Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy. Cancer Research. 75: 1944-8. PMID 25808865 DOI: 10.1158/0008-5472.Can-14-3602  0.771
2015 Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1273-80. PMID 25320358 DOI: 10.1158/1078-0432.Ccr-14-1220  0.633
2015 Gao S, Gao Y, He H, Brown M, Balk S, Cai C. Abstract 966: LSD1 functions as a global androgen receptor coactivator and is a therapeutic target in prostate cancer Cancer Research. 75: 966-966. DOI: 10.1158/1538-7445.Am2015-966  0.7
2015 Gao Y, Gao S, He H, Liu X, Chen S, Ma F, Liu XS, Brown M, Balk SP, Chen S, Cai C. Abstract 1849: Androgen receptor transcriptionally represses genes mediating DNA synthesis and repair in prostate cancer Cancer Research. 75: 1849-1849. DOI: 10.1158/1538-7445.Am2015-1849  0.762
2014 Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen S, Chen MW, Zhang J, Ahmed M, Wang Y, Metzger E, Schüle R, Liu XS, Brown M, et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Reports. 9: 1618-27. PMID 25482560 DOI: 10.1016/J.Celrep.2014.11.008  0.677
2014 Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4075-85. PMID 24874833 DOI: 10.1158/1078-0432.Ccr-14-0292  0.603
2014 Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1590-600. PMID 24449822 DOI: 10.1158/1078-0432.Ccr-13-1863  0.686
2014 Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis Oncogene. 33: 2815-2825. PMID 23752196 DOI: 10.1038/Onc.2013.235  0.65
2013 Cai C, Yuan X, Balk SP. Androgen receptor epigenetics. Translational Andrology and Urology. 2: 148-157. PMID 25580383 DOI: 10.3978/J.Issn.2223-4683.2013.09.02  0.661
2013 Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, et al. Discovery of a selective irreversible BMX inhibitor for prostate cancer. Acs Chemical Biology. 8: 1423-8. PMID 23594111 DOI: 10.1021/Cb4000629  0.521
2013 Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. The Journal of Clinical Investigation. 123: 1109-22. PMID 23426182 DOI: 10.1172/Jci66666  0.734
2013 Xu K, Wu ZJ, Groner AC, He HH, Cai C, Stack EC, Loda M, Liu T, Morrissey C, Vessella RL, Kantoff PW, Balk SP, Liu XS, Brown M. Polycomb-independent activity of EZH2 in castration resistant prostate cancer Epigenetics & Chromatin. 6. DOI: 10.1186/1756-8935-6-S1-O14  0.643
2013 Cai C, He HH, Brown M, Balk SP. Abstract A46: LSD1 globally mediates epigenetic modifications on androgen receptor-dependent enhancers Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-A46  0.605
2012 Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (New York, N.Y.). 338: 1465-9. PMID 23239736 DOI: 10.1126/Science.1227604  0.691
2012 Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby AC. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Molecular Endocrinology (Baltimore, Md.). 26: 1836-46. PMID 23023563 DOI: 10.1210/Me.2012-1222  0.587
2012 Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. The Journal of Biological Chemistry. 287: 8571-83. PMID 22275373 DOI: 10.1074/Jbc.M111.325290  0.692
2012 Cai C, Hsieh CL, Gao S, Kannan A, Bhansali M, Govardhan K, Dutta R, Shemshedini L. Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer. Molecular Endocrinology (Baltimore, Md.). 26: 292-307. PMID 22174378 DOI: 10.1210/Me.2010-0394  0.86
2012 Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan X. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. The Journal of Biological Chemistry. 287: 2090-8. PMID 22139837 DOI: 10.1074/Jbc.M111.323303  0.618
2012 Cai C, He H, Brown M, Balk S. Abstract IA8: Mechanisms regulating distinct AR transcriptional programs in PCa Cancer Research. 72: IA8-IA8. DOI: 10.1158/1538-7445.Prca2012-Ia8  0.691
2012 Cai C, He H, Chen S, Liu XS, Brown M, Balk SP. Abstract B12: LSD1 mediates global AR transcription suppression in prostate cancer cells Cancer Research. 72: B12-B12. DOI: 10.1158/1538-7445.Prca2012-B12  0.694
2011 Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 20: 457-71. PMID 22014572 DOI: 10.1016/J.Ccr.2011.09.001  0.787
2011 Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Research. 71: 6503-13. PMID 21868758 DOI: 10.1158/0008-5472.Can-11-0532  0.737
2011 Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocrine-Related Cancer. 18: R175-82. PMID 21712345 DOI: 10.1530/Erc-10-0339  0.646
2011 Cai C, Balk SP. Abstract LB-420: Intratumoral de novo steroid synthesis mediates prostate cancer resistance to androgen deprivation and CYP17a1 inhibition Endocrinology. 71. DOI: 10.1158/1538-7445.Am2011-Lb-420  0.625
2009 Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Research. 69: 6027-32. PMID 19584279 DOI: 10.1158/0008-5472.Can-09-0395  0.781
2009 Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Research. 69: 5202-9. PMID 19491261 DOI: 10.1158/0008-5472.Can-09-0026  0.759
2008 Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells. Journal of Molecular Endocrinology. 41: 13-23. PMID 18469090 DOI: 10.1677/Jme-07-0158  0.876
2007 Cai C, Hsieh CL, Shemshedini L. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Molecular Cancer Research : McR. 5: 725-35. PMID 17634427 DOI: 10.1158/1541-7786.Mcr-06-0430  0.849
2007 Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Molecular Endocrinology (Baltimore, Md.). 21: 1835-46. PMID 17505060 DOI: 10.1210/Me.2006-0480  0.824
2007 Cai C, Omwancha J, Hsieh CL, Shemshedini L. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer and Prostatic Diseases. 10: 39-45. PMID 17003774 DOI: 10.1038/sj.pcan.4500912  0.819
2007 Cai C, Chen SY, Zheng Z, Omwancha J, Lin MF, Balk SP, Shemshedini L. Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation. Oncogene. 26: 1606-15. PMID 16964290 DOI: 10.1038/Sj.Onc.1209956  0.831
2006 Omwancha J, Zhou XF, Chen SY, Baslan T, Fisher CJ, Zheng Z, Cai C, Shemshedini L. Makorin RING finger protein 1 (MKRN1) has negative and positive effects on RNA polymerase II-dependent transcription. Endocrine. 29: 363-73. PMID 16785614 DOI: 10.1385/Endo:29:2:363  0.742
2006 Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL, Shemshedini L. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene. 25: 7212-23. PMID 16732317 DOI: 10.1038/sj.onc.1209705  0.815
2006 Zheng Z, Cai C, Omwancha J, Chen SY, Baslan T, Shemshedini L. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. The Journal of Biological Chemistry. 281: 4002-12. PMID 16361251 DOI: 10.1074/Jbc.M509260200  0.827
Show low-probability matches.